Filtered By:
Condition: Rheumatoid Arthritis

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 493 results found since Jan 2013.

Management of Cardiovascular Disease Risk in Rheumatoid Arthritis
J Clin Med. 2022 Jun 17;11(12):3487. doi: 10.3390/jcm11123487.ABSTRACTCardiovascular diseases, including ischemic heart disease and stroke, reportedly comprise the top two causes of global mortality [...].PMID:35743556 | DOI:10.3390/jcm11123487
Source: Atherosclerosis - June 24, 2022 Category: Cardiology Authors: Patrick H Dessein Miguel A Gonzalez-Gay Source Type: research

Rheumatoid arthritis and the risk of major cardiometabolic diseases: a Mendelian randomization study
CONCLUSION: Genetically determined RA was associated with increased risks of T2D and CAD, suggesting that RA plays a crucial role in the pathogenesis of T2D and CAD.PMID:35658786 | DOI:10.1080/03009742.2022.2070988
Source: Scandinavian Journal of Rheumatology - June 6, 2022 Category: Rheumatology Authors: K Zhang Y Jia R Wang D Guo P Yang L Sun Y Wang F Liu Y Zang M Shi Y Zhang Z Zhu Source Type: research

The effect of statin on major adverse cardiovascular events and mortality in patients with rheumatoid arthritis - a systematic review and meta-analysis
CONCLUSIONS: This systematic review and meta-analysis showed that statin was associated with reduction of MACE and mortality in patients with RA.PMID:35587067 | DOI:10.26355/eurrev_202205_28734
Source: Pharmacological Reviews - May 19, 2022 Category: Drugs & Pharmacology Authors: A R Rahmadi R Pranata W M Raffaello E Yonas M P Ramadhian M R R Natadikarta M R Akbar Source Type: research

Genetic liability to rheumatoid arthritis in relation to coronary artery disease and stroke risk
ConclusionThis study found that genetic liability to RA was associated with increased risk of CAD and intracerebral hemorrhage and that the association for CAD might be mediated by CRP. The heightened cardiovascular risk should be actively monitored and managed in RA patients, and this may include damping systemic inflammation.
Source: Arthritis and Rheumatology - May 18, 2022 Category: Rheumatology Authors: Shuai Yuan, Paul Carter, Amy M. Mason, Fangkun Yang, Stephen Burgess, Susanna C. Larsson Tags: Full Length Source Type: research

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
Conclusions We did not find evidence for an increased risk of cardiovascular outcomes with tofacitinib in patients with RA treated in the real-world setting; however, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors. Trial registration number NCT04772248.
Source: Annals of the Rheumatic Diseases - May 16, 2022 Category: Rheumatology Authors: Khosrow-Khavar, F., Kim, S. C., Lee, H., Lee, S. B., Desai, R. J. Tags: ARD, Rheumatoid arthritis Source Type: research